
PRODUCT INFORMATION

Vazegepant (hydrochloride)

Item No. 46217



CAS Registry No.:	1414976-20-7
Formal Name:	4-(1,2-dihydro-2-oxo-3-quinolinyl)-N-[(1R)-1-[(7-methyl-1H-indazol-5-yl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]-1-piperidinecarboxamide, monohydrochloride
Synonyms:	BHV 3500, BMS-742413, Zavegepant
MF:	$C_{36}H_{46}N_8O_3$ • HCl
FW:	675.3
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Vazegepant (hydrochloride) is supplied as a solid. A stock solution may be made by dissolving the vazegepant (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Vazegepant (hydrochloride) is sparingly soluble (1-10 mg/ml) in ethanol and DMSO.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of vazegepant (hydrochloride) can be prepared by directly dissolving the solid in aqueous buffers. Vazegepant (hydrochloride) sparingly soluble (1-10 mg/ml) in PBS (pH 7.2). We do not recommend storing the aqueous solution for more than one day.

Description

Vazegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist (K_i = 23 pM in SK-N-MC membrane preparations).[1] It is >10,000-fold selective for the CGRP receptor over the adrenomedullin receptor 1 (AM_1 receptor), AM_2 receptor, calcitonin (CT) receptor, amylin 1 (AMY_1) receptor, and AMY_3 receptor. *Ex vivo*, vazegepant reverses CGRP-induced dilation of human intracranial arteries (EC_{50} = 880 pM) but does not induce contractions in human coronary arteries when used at concentrations up to 10 µM. It reduces human α-CGRP-induced increases in facial blood flow in marmosets when administered subcutaneously at a dose of 0.03 mg/kg. Formulations containing vazegepant have been used in the treatment of migraines.

Reference

1. Chaturvedula, P.V., Mercer, S.E., Pin, S.S., *et al*. Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): A potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery. *Bioorg. Med. Chem. Lett.* **23(11)**, 3157-3161 (2013).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/25/2026

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM